Although recent developments such as CAR-T therapy11 and anti-CD19 based therapy such as Blinatumomab12 have raised hope for such patients13, antigen escape and lineage infidelity in MLL-translocated leukemia have proved problematic14. Here, KMT2A is linked to leukemia.